Positron emission tomography in neurological and psychiatric disorders

2012 ◽  
Vol 22 (1) ◽  
pp. 2-17 ◽  
Author(s):  
Andrew Newberg ◽  
Daniel Monti ◽  
Aleeze Moss ◽  
Abass Alavi
2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
P. Falkai

In the first half of the last century researchers believed that severe mental disorders like schizophrenia have a neuropathological basis. Up to now it has been difficult to prove any consistent core finding for this disorder. Reason for this might be that it is a network disorder and therefore regional specific findings will unlikely be found. Parallel to that describing the dopamine hypothesis of schizophrenia and the catechol amine deficit hypothesis of depression were very helpful for understanding the mechanisms of antipsychotics and antidepressants working in these disorders. Especially the introduction of the positron emission tomography has helped to link symptoms with the transmitter systems. However, none of these findings are specific for schizophrenia or depression. During the talk it will be discussed when the combination of core clinical symptoms, imaging findings and genetic variables are helpful for a future classification of psychiatric disorders.


1990 ◽  
Vol 156 (5) ◽  
pp. 615-619 ◽  
Author(s):  
John L. Waddington

Over the past several years there has emerged a family of highly sophisticated but technically complex procedures for the visualisation of a range of cerebral functions in living man (Andreasen, 1988). The images they produce are so beguiling not just because of their potential to give new insights into the pathophysiology and treatment of major psychiatric disorders, but because they convey information through a quite fundamental modality: people are only convinced by what they can see. However, initial applications of such new technology have appeared just as likely to generate new questions and contradictions as to provide answers to current issues. This is readily illustrated by recent studies on the imaging of brain dopamine receptors in schizophrenic patients by positron emission tomography (PET) (see Waddington, 1989a).


2018 ◽  
Vol 40 (3) ◽  
pp. 342-350 ◽  
Author(s):  
Matthew E. Sloan ◽  
Caroline W. Grant ◽  
Joshua L. Gowin ◽  
Vijay A. Ramchandani ◽  
Bernard Le Foll

1989 ◽  
Vol 29 (3) ◽  
pp. 351-352 ◽  
Author(s):  
W.-D. Heiss ◽  
G. Pawlik ◽  
K. Herholz ◽  
B. Szelies ◽  
K. Wienhard

2011 ◽  
Vol 1228 (1) ◽  
pp. E13-E25 ◽  
Author(s):  
Andrew B. Newberg ◽  
Aleeze S. Moss ◽  
Daniel A. Monti ◽  
Abass Alavi

1989 ◽  
Vol 154 (4) ◽  
pp. 433-436 ◽  
Author(s):  
John L. Waddington

There can be few more impressive sights in contemporary neuroscience and biological psychiatry than the imaging of neurotransmitter receptors in the brains of living human subjects by positron emission tomography (PET; Sedvall et al, 1986). How has such technology advanced our understanding of the pathophysiology and/or treatment of major psychiatric disorders?


Author(s):  
Shalini Narayana ◽  
Andrew B. Newberg ◽  
Abass Alavi

This chapter describes the application of positron emission tomography (PET) technology to study neurotransmitter systems. The process of developing radiotracers to study the neurotransmitter systems, namely radioligands and the technical aspects of utilizing these radiotracers in PET imaging, is discussed. Normal distribution of neurotransmitters including dopamine, serotonin, opioids, and γ-aminobutyric acid (GABA), as well as abnormalities of these systems in various neurological and psychiatric disorders, are highlighted. The chapter provides evidence that radioligand imaging has been useful not only in delineating pathophysiological processes in psychiatric disorders, but also in contributing to the diagnosis, prognosis, and disease course, and in assessing drug effects. Recent advances in receptor imaging that are rapidly gaining clinical relevance are also discussed.


Sign in / Sign up

Export Citation Format

Share Document